with regard to aspects of the invention any ang ii antagonist can be suitable , unless otherwise specified , e . g . the sartans such as candesartan , eprosartan , irbesartan , losartan , telmisartan , valsartan , olmesartan and tasosartan mentioned hereinbefore , preferably losartan or telmisartan , most preferred telmisartan { 4 ′-[ 2 - n - propyl - 4 - methyl - 6 -( 1 - methylbenzimidazol - 2 - yl ) benzimidazol - 1 - ylmethyl ] biphenyl - 2 - carboxylic acid } and the pharmaceutically acceptable salts thereof , furthermore , any ace inhibitor can be used with regard to aspects of the invention mentioned hereinbefore , unless otherwise specified , e . g . benazepril , captopril , ceronapril , enalapril , fosinopril , imidapril , lisinopril , moexipril , quinapril , ramipril , trandolapril and perindopril , preferably captopril , enalapril , lisinopril and ramipril , most preferred ramipril . in a preferred embodiment of the method - of - treatment aspect ramipril is co - administered with an ang ii antagonist . in a second preferred embodiment of the method - of - treatment aspect an ace inhibitor is co - administered with telmisartan . in a third preferred embodiment of the method - of - treatment aspect ramipril is co - administered with telmisartan . co - administration of an ang ii antagonist and an ace inhibitor is meant to include administration sequential in time or simultaneous administration , the simultaneous administration being preferred . for sequential administration , the ang ii antagonist can be administered before or after administration of the ace inhibitor . the active compounds can be administered orally , bucally , parenterally , by inhalation spray , rectally or topically , the oral administration being preferred . parenteral administration may include subcutaneous , intravenous , intramuscular and intrasternal injections and infusion techniques . the active compounds can be orally administered in a wide variety of different dosage forms , i . e ., they may be formulated with various pharmaceutically acceptable inert carriers in the form of tablets , capsules , lozenges , troches , hard candies , powders , sprays , aqueous suspensions , elixirs , syrups , and the like . such carriers include solid diluents or fillers , sterile aqueous media and various non - toxic organic solvents , etc . moreover , such oral pharmaceutical formulations can be suitably sweetened and / or flavored by means of various agents of the type commonly employed for such purposes . in general , the compounds of this invention are present in such oral dosage forms at concentration levels ranging from about 0 . 5 % to about 90 % by weight of the total composition , in amounts which are sufficient to provide the desired unit dosages . other suitable dosage forms for the compounds of this invention include controlled release formulations and devices well known to those who practice in the art . for purposes of oral administration , tablets containing various excipients such as sodium citrate , calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch , alginic acid and certain complex silicate , together with binding agents such as polyvinylpyrrolidone , sucrose , gelatin and acacia . additionally , lubricating agents such as magnesium stearate , sodium lauryl sulfate and talc or compositions of a similar type may also be employed as fillers in soft and hard - filled gelatin capsules ; included lactose or milk sugar as well as high molecular weight polyethylene glycols . when aqueous suspensions and / or elixirs are desired for oral administration , the essential active ingredient therein may be combined with various sweetening or flavoring agents , colouring matter or dyes and , if so desired , emulsifying agents and / or water , ethanol , propylene glycol , glycerin and various like combinations thereof . for purposes of parenteral administration , solutions of the compounds in sesame or peanut oil or in aqueous propylene glycol may be employed , as well as sterile aqueous solutions of the corresponding pharmaceutically - acceptable salts . such aqueous solutions should be suitably buffered if necessary , and the liquid diluent rendered isotonic with sufficient saline or glucose . these particular aqueous solutions are especially suitable for intravenous , intramuscular and sub - cutaneous injection purposes . in this connection , the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art . for instance , distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass filter or a diatomaceous - earth or unglazed porcelain filter . preferred filters of this type include the berkefeld , the chamberland and the asbestos disk - metal seitz filter , wherein the fluid is sucked into a sterile container with the aid of a suction pump . the necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition . for purposes of transdermal administration , the dosage form of the particular compound or compounds may include , by way of example , solutions , lotions , ointments , creams , gels , suppositories , rate - limiting sustained release formulations and devices therefor . such dosage forms comprise the particular compound or compounds and may include ethanol , water , penetration enhancer and inert carriers such as gel - producing materials , mineral oil , emulsifying agents , benzyl alcohol and the like . several ang ii inhibitors are already on the market and can be used for administration , e . g . micardis ®, lorzaar ®, cozaar ®, lortaan ®, losaprex ®, neo - lotan ® or oscaar ®, approvel ®, karvea ®, diovan ®, atacand ®, blopresse and teveten ®. also several ace - inhibitors are already on the market and can be used for administration , e . g . briem ®, cibacen ®, cibacne ®, lotensin ®, dynacil ®, elidiur ®, fosinorm ®, fositen ®, fozitec ®, monopril ®, staril ®, tensozide ®, novaloc ®, tanapril ®, fempress ®, perdix ®, univasc ®, accupril ®, accuprin ®, accupro ®, acequin ®, acuitel ®, korec ®, quinazil ®, xanef ®, pres ®, acerbon ®, lopirin ®, tensobon ®, delix ® or vesdil ®. the ace inhibitor may be administered in a daily dosage of 1 . 25 mg ( or 0 . 018 mg / kg , based on a person of 70 kg ) to 450 mg ( 6 . 429 mg / kg ) orally and of about 20 mg ( 0 . 286 mg / kg ) parenterally , preferably of 5 mg ( 0 . 071 mg / kg ) to 100 mg ( 1 . 429 mg / kg ) orally . particularly preferred is an oral daily dosage of 2 . 5 mg ( 0 . 036 mg / kg ) to 10 mg ( 0 . 143 mg / kg ). the ang ii antagonist may be administered in a daily dosage of 10 mg ( or 0 . 143 mg / kg , based on a person of 70 kg ) to 500 mg ( 7 . 143 mg / kg ) orally and of about 20 mg ( 0 . 286 mg / kg ) parenterally , preferably of 20 mg ( 0 . 286 mg / kg ) to 100 mg ( 1 . 429 mg / kg ) orally . particularly preferred is an oral daily dosage of 40 mg ( 0 . 571 mg / kg ) to 80 mg ( 1 . 143 mg / kg ). in all administration modes and dosages mentioned hereinbefore the preferred ace inhibitor is ramipril and the preferred ang ii antagonist is telmisartan . in the most preferred embodiment ramipril is administered simultaneously in a daily dosage of about 10 mg together with telmisartan in a daily dosage of about 80 mg via the oral route . pharmaceutical compositions comprising one ace inhibitor in an amount of 1 . 25 mg to 450 mg and one ang ii antagonist in an amount of 10 mg to 500 mg in single dosage units , optionally together with one or more pharmaceutically acceptable diluents and / or carriers , could be used for the method of treatment aspect of the invention . for instance , pharmaceuticals comprising one ace inhibitor selected from benazepril , captopril , ceronapril , enalapril , fosinopril , imidapril , lisinopril , moexipril , quinapril , ramipril , trandolapril and perindopril in an amount of 1 . 25 mg to 100 mg and one ang ii antagonist selected from candesartan , eprosartan , irbesartan , losartan , telmisartan and valsartan , olmesartan , tasosartan in an amount of 20 to 100 mg in single dosage units , optionally together with one or more pharmaceutically acceptable diluents and / or carriers would be suitable for the method of treatment according to the invention . the most preferred pharmaceutical compositions comprise as ace inhibitor ramipril in an amount of 1 . 25 mg to 100 mg and as ang ii antagonist telmisartan in an amount of 20 mg to 100 mg , in single dosage units , optionally together with one or more pharmaceutically acceptable diluents and / or carriers . especially preferred pharmaceutical compositions comprise as ace inhibitor ramipril in an amount of about 10 mg and as ang ii antagonist telmisartan in an amount of about 80 mg in single dosage units , optionally together with one or more pharmaceutically acceptable diluents and / or carriers . as already mentioned above the present invention also provides the use of an ang ii antagonist for manufacture of a pharmaceutical composition for the treatment of the human or non - human mammalian body for treating the indications mentioned hereinbefore when used in combination with an ace inhibitor . this use aspect is meant to include the manufacture of all pharmaceutical compositions mentioned hereinbefore .
the invention relates to a method of treatment of dementia and / or regression of cognitive function , comprising co - administration of effective amounts of an angiotensin ii antagonist and an angiotensin i converting enzyme inhibitor , pharmaceutical compositions containing an angiotensin ii antagonist together with an ace inhibitor and the use of an angiotensin ii antagonist and an ace inhibitor for the manufacture of corresponding pharmaceutical compositions .